Stocks · News reference
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.49% on an annualized basis producing an average annual return of 25.33%. Currently, argenx has a market capitalization of $60.86 billion.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.
Read original at globenewswire-incWells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1350 to $1415.
Read original at benzinga